-
Mashup Score: 7Dr Liu Previews ASCO 2024 Lung Cancer Data - 1 day(s) ago
Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Dr Liu Previews ASCO 2024 Lung Cancer Data - 5 day(s) ago
Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8ASCO Issues Updated Guidelines for Stage IV NSCLC With and Without Driver Alterations - 6 day(s) ago
ASCO has issued new evidence-based updates to two living guidelines on the treatment of stage IV NSCLC with and without driver alterations.
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Dr Liu Previews ASCO 2024 Lung Cancer Data - 7 day(s) ago
Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations - 1 month(s) ago
This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical decision-making queries encountered in everyday practice, such as the optimal treatment strategy for PD-L1–high patients, predictive factors for response to immune checkpoint inhibitors (ICI) both in terms of patient and cancer characteristics, the potential benefits of dual checkpoint blockade, and the unresolved issue of safe discontinuation strategies for long-term responders. Around one in five patients falls into this latter category while the majority develop either primary or acquired resistance to ICI-based first-line therapy, necessitating effective subsequent lines of treatment. Docetaxel, with or without combination of antiangiogenic agents, serves as the backbone of treatment, although evidence in the post-ICI setting is limited. Given that an inflamed tumor microenvironment (TME) is crucia
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Dr @StephenVLiu of @LombardiCancer discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC. @ASCO #ASCO24 #lcsm https://t.co/Ujlfiq6eZk